Anti-MAG Neuropathy: Development of a Therapeutic Glycopolymer: MIP: Polyneuron Pharmaceuticals AG

• Unité de recherche: INNOSUISSE
• Numéro de projet: 17485.1 PFLS-LS
• Titre du projet anglais: Anti-MAG Neuropathy: Development of a Therapeutic Glycopolymer: MIP: Polyneuron Pharmaceuticals AG

Description succincte (Allemand)

Anti-MAG Neuropathy: Development of a Therapeutic Glycopolymer

Description succincte (Anglais)

Anti-MAG Neuropathy: Development of a Therapeutic Glycopolymer: MIP: Polyneuron Pharmaceuticals AG

Résumé des résultats (Abstract) (Allemand)

The aim of this project is to define preclinical lead candidates for the treatment of anti-myelin-associated|glycoprotein (MAG) neuropathy, a disabling IgM autoantibody-mediated autoimmune disorder of the|peripheral nervous system. Currently, there is no effective treatment and agents to block/deplete the|pathogenic autoantibodies are of substancial clinical interest. Several lead candidates (glycopolymers) will|be synthesized and evaluated in an animal model of the disease.

Résumé des résultats (Abstract) (Anglais)

The aim of this project is to define preclinical lead candidates for the treatment of anti-myelin-associated|glycoprotein (MAG) neuropathy, a disabling IgM autoantibody-mediated autoimmune disorder of the|peripheral nervous system. Currently, there is no effective treatment and agents to block/deplete the|pathogenic autoantibodies are of substancial clinical interest. Several lead candidates (glycopolymers) will|be synthesized and evaluated in an animal model of the disease.